Ganitumab

Ganitumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IGF-1R
Clinical data
ATC code	none;
Identifiers
CAS Number	905703-97-1 ;
ChemSpider	none;
UNII	CK1441RCZ8;
KEGG	D09908 ;
Chemical and physical data
Formula	C6472H10028N1728O2020S42
Molar mass	145712.01 g·mol−1
	(what is this?) (verify)

Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.^[1]^[2]

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.^[3]^[4]

References

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.
^ Martínez P, Sales Fidalgo PA, Felip E (October 2014). "Ganitumab for the treatment of small-cell lung cancer". Expert Opinion on Investigational Drugs. 23 (10): 1423–32. doi:10.1517/13543784.2014.951434. PMID 25189625. S2CID 7318164.
^ "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23.
^ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.

[Martínez_2014-2] Martínez P, Sales Fidalgo PA, Felip E (October 2014). "Ganitumab for the treatment of small-cell lung cancer". Expert Opinion on Investigational Drugs. 23 (10): 1423–32. doi:10.1517/13543784.2014.951434. PMID 25189625. S2CID 7318164.

[3] "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23.

[4] "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.

[1]

[2]

[3]

[4]